Foresite Capital Management V, LLC, a 10%+ owner of Latigo Biotherapeutics, Inc. (LTGO), disclosed an open-market purchase of 140,000 shares on August 10, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were bought at $18.00 apiece, for a total transaction value of $2,520,000.00.
This was a straightforward open-market buy — meaning Foresite used its own capital to acquire the stock at the prevailing market price, rather than receiving shares through options, grants, or other compensation-linked mechanisms. Purchases of this kind are generally viewed by market watchers as a more direct signal of investor conviction, since they involve real money changing hands at current valuations rather than the exercise of previously granted equity.
Following the transaction, Foresite Capital Management V, LLC now holds 2,008,024 shares of Latigo Biotherapeutics, all held indirectly, likely through a fund or investment vehicle structure typical of institutional biotech investors. As a 10%+ owner, Foresite’s continued accumulation keeps its stake well above the reporting threshold that triggers ongoing disclosure obligations under SEC rules.
Context on the Filing
We first covered this same disclosure in detail shortly after it was filed; readers looking for the original breakdown of the transaction can find it in our earlier report, Latigo Biotherapeutics (LTGO) Insider Buys $2.52M in Shares. That piece and this one draw on the same underlying Form 4 data, but this report focuses on situating the transaction within the broader context of how large shareholders build positions over time.
Academic research on insider trading patterns has found that clustered buying activity — particularly from significant shareholders like Foresite — can statistically correlate with subsequent stock performance over certain time horizons. That said, this correlation is a historical pattern observed across large datasets of filings, not a predictive guarantee tied to any single transaction, and this report should not be read as guidance to buy or sell shares of Latigo Biotherapeutics.
Form 4 filings like this one are public records required whenever officers, directors, or major shareholders buy or sell company stock, and they offer a window into how those closest to a company are positioning themselves. Additional filings from Foresite or other Latigo insiders, if made, would be expected to appear in subsequent SEC disclosures.
→ See all LTGO coverage on WhoIsBuyingNow
Source: original SEC Form 4 filing.